Back in 2014, Roche spent $725 million upfront on Seragon Pharmaceuticals, but three years down the line, it has now canned work on its leading drug, ARN-810.
In its first-quarter results announced today, the Swiss major quietly announced that the next-gen SERD drug, RG6046, has been “removed from phase 2” in HER negative advanced breast cancer.
No other details were given, but the compound appears to have been removed from the company’s roster of pipeline meds.
Roche paid $725 million (with $1 billion in biobucks) for Seragon, a privately held biotech based in San Diego, California, three years ago.
Roche got access to Seragon’s entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer. ARN-810 had been leading that pack, and was in phase 1 when it was subsumed into Roche.
Other meds from its buyout are still lined up in its pipeline, however, including RG6047 (GDC-0927, or ARN-927).
By Ben Adams
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
